Adria Suarez Mora, MD


Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy

Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.

Adrian Wiestner, MD, PhD


Dr. Wiestner Discusses Findings From the Phase III HELIOS Trial

Adrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.

Adriana Rossi, MD, Weill Cornell Medical College


Relapsed/Refractory Multiple Myeloma: Future Directions in Care

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.

Adrienne Hill, DO


Impairment-Driven Cancer Rehabilitation Improves Survivors' Quality of Life

The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.

Adrienne Phillips, MD, MPH


Dr. Phillips Discusses the Treatment of ATLL

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

Afonso Ribeiro, MD


Dr. Ribeiro on the Role of Surgery in Pancreatic Cancer

Afonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.

Afsaneh Barzi, MD


Dr. Barzi on Combination Regorafenib and Pembrolizumab in MSS CRC

Afsaneh Barzi, MD, PhD, discusses the combination of regorafenib and pembrolizumab in patients with microsatellite stable colorectal cancer.

Ã…ge Schultz, DVM, PhD


Ã…ge Schultz, DVM, PhD, Discusses the Cost of Supportive Care Medicine

Ã…ge Schultz, DVM, PhD, executive director, Multinational Association of Supportive Care in Cancer (MASCC), discusses pain management and the cost of supportive care medicine.

Agne Paner, MD


Dr. Paner on HORIZON Trial in Multiple Myeloma

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Agnieszka Janus, MD, PhD


Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell Leukemia

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.

Agustin A. Garcia, MD


Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer

The evaluation of noncytotoxic agents for the treatment of epithelial ovarian cancer has produced encouraging findings in recent months, which has led to the approval of new agents with novel mechanisms of action and continuing studies into many more potential therapies.

Ahmad Halwani, MD


It's Time to Tackle the Evidence Gap in Lymphoid Cancers

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Ahmad Tarhini, MD, PhD


Dr. Tarhini on Recent Practice-Changing Clinical Trials in Melanoma

Ahmad Tarhini, MD, PhD, director, Melanoma and Skin Cancer Program, Center for Immuno-Oncology Research, Cleveland Clinic, discusses some recent practice-changing clinical trials in melanoma.

Ahmed A. Hussein Aly, MD, PhD


Robot-Assisted Cystectomy Is Feasible for Many Patients With Bladder Cancer

To determine the 10-year oncologic outcomes and recurrence patterns after robot-assisted radical cystectomy, a group within the Department of Urology at Roswell Park Comprehensive Cancer Center performed a retrospective review.

Ahmed Galal, MD


Dr. Galal on Managing AEs Linked With CAR T-Cell Therapy

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.

Ahmed N. Al-Niaimi, MD


Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian Cancer

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

Ahmed O. Kaseb, MD


Dr. Kaseb on Safety Profile of Atezolizumab Plus Bevacizumab in HCC

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Ahmet Dogan, MD, PhD


Dr. Dogan on Updated WHO Classifications in DLBCL

Ahmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).

Aileen M. Soper, BA


NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

Aiwu Ruth He, MD


Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

Aiwu Ruth He, MD, PhD


Advanced Biliary Tract Cancers: Novel Biomarker Strategies

Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.

Ajai Chari, MD, PhD


Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Ajai Chari, MD, Mount Sinai Health System


Dr. Chari on the Role of MRD Testing in Multiple Myeloma

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

Ajai Chari, MD, Mount Sinai Hospital


Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.